{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:30Z","timestamp":1793805930256,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jocn.2026.112185","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:31:47Z","timestamp":1784086307000},"page":"112185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study"],"prefix":"10.1016","volume":"152","author":[{"given":"Daniele","family":"Armocida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bianconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cofano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Fiaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Salvati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Zona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Denaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Frati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Spetger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rud\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Garbossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Ius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jocn.2026.112185_b0005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002995","article-title":"Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)","volume":"9","author":"Lau","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jocn.2026.112185_b0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jocn.2026.112185_b0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11864-020-00733-z","article-title":"Current Treatment of Melanoma Brain Metastasis","volume":"21","author":"Rishi","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"20","key":"10.1016\/j.jocn.2026.112185_b0020","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1200\/JCO.22.00333","article-title":"Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline","volume":"40","author":"Schiff","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112185_b0025","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2026.112185_b0030","doi-asserted-by":"crossref","unstructured":"Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rud\u00e0 R, Preusser M; EANO Executive Board and ESMO Guidelines Committee. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017 Jul 1;28(suppl_4):iv84-iv99. doi: 10.1093\/annonc\/mdx221.","DOI":"10.1093\/annonc\/mdx221"},{"issue":"1","key":"10.1016\/j.jocn.2026.112185_b0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/neuonc\/noz147","article-title":"Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression","volume":"22","author":"Galldiks","year":"2020","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2026.112185_b0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"10.1016\/j.jocn.2026.112185_b0045","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1002\/cncr.26724","article-title":"NRAS mutation status is an independent prognostic factor in metastatic melanoma","volume":"118","author":"Jakob","year":"2012","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jocn.2026.112185_b0050","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"Network","year":"2015","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.jocn.2026.112185_b0055","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jocn.2026.112185_b0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jocn.2026.112185_b0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jocn.2026.112185_b0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"9","author":"Ascierto","year":"2012","journal-title":"J Transl Med"},{"issue":"4","key":"10.1016\/j.jocn.2026.112185_b0075","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3390\/biomedicines10040822","article-title":"The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma","volume":"10","author":"Ernst","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.jocn.2026.112185_b0080","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1177\/03008916231179251","article-title":"Outcomes in patients with BRAFV600-mutated melanoma and brain metastases at baseline treated with dabrafenib plus trametinib","volume":"109","author":"Aglietta","year":"2023","journal-title":"Tumori"},{"key":"10.1016\/j.jocn.2026.112185_b0085","doi-asserted-by":"crossref","unstructured":"Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Brochez L, Del Marmol V, Dr\u00e9no B, Eggermont AMM, Fargnoli MC, Forsea AM, H\u00f6ller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebb\u00e9 C, Leiter U, Longo C, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stockfleth E, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P, Mandala M; European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024. Eur J Cancer. 2025 Jan 17;215:115152. doi: 10.1016\/j.ejca.2024.115152.","DOI":"10.1016\/j.ejca.2024.115152"},{"key":"10.1016\/j.jocn.2026.112185_b0090","doi-asserted-by":"crossref","unstructured":"Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, Daniels GA, DiMaio D, Fields RC, Fleming MD, Freeman M, Galan A, Gastman B, Guild V, Johnson D, Joseph RW, Lange JR, Nath S, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Wuthrick E, McMillian NR, Engh AM. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402. doi: 10.6004\/jnccn.2019.0018.","DOI":"10.6004\/jnccn.2019.0018"},{"issue":"3","key":"10.1016\/j.jocn.2026.112185_b0095","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study","volume":"26","author":"Long","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jocn.2026.112185_b0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jocn.2019.12.063","article-title":"Metastatic melanoma: Surgical treatment of brain metastases - Analysis of 110 patients","volume":"73","author":"McHugh","year":"2020","journal-title":"J Clin Neurosci"},{"issue":"10","key":"10.1016\/j.jocn.2026.112185_b0105","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1158\/1078-0432.CCR-12-2936","article-title":"The imaging viewpoint: how imaging affects determination of progression-free survival","volume":"19","author":"Sullivan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jocn.2026.112185_b0110","first-page":"828","article-title":"Melanoma Brain Metastases: a Systematic Review of Opportunities for Earlier Detection, Diagnosis, and Treatment","volume":"13","author":"Diaz","year":"2023","journal-title":"Life (Basel)"},{"issue":"12","key":"10.1016\/j.jocn.2026.112185_b0115","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/cncr.33459","article-title":"Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies","volume":"127","author":"Bander","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jocn.2026.112185_b0120","doi-asserted-by":"crossref","unstructured":"Millington GW. Mutations of the BRAF gene in human cancer, by Davies etal. (Nature 2002; 417: 949-54). Clin Exp Dermatol. 2013 Mar;38(2):222-3. doi: 10.1111\/ced.12015.","DOI":"10.1111\/ced.12015"},{"issue":"10","key":"10.1016\/j.jocn.2026.112185_b0125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41582-020-0391-x","article-title":"Management of brain metastases according to molecular subtypes","volume":"16","author":"Soffietti","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2026.112185_b0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3171\/2011.3.JNS091107","article-title":"Surgical management of melanoma brain metastases in patients treated with immunotherapy","volume":"115","author":"Lonser","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.jocn.2026.112185_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2024.05.011","article-title":"Anamnestic radiological metastases outcome surgical score (ARMO-S). a purpose of a predictive surgical scoring system for brain metastases","volume":"125","author":"Armocida","year":"2024","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.jocn.2026.112185_b0140","doi-asserted-by":"crossref","unstructured":"Armocida D, Arcidiacono UA, Palmieri M, Pesce A, Cofano F, Picotti V, Salvati M, D'Andrea G, Garbossa D, Santoro A, Frati A. Intracranial Meningioma in Elderly Patients. Retrospective Multicentric Risk and Surgical Factors Study of Morbidity and Mortality. Diagnostics (Basel). 2022 Jan 29;12(2):351. doi: 10.3390\/diagnostics12020351.","DOI":"10.3390\/diagnostics12020351"},{"key":"10.1016\/j.jocn.2026.112185_b0145","doi-asserted-by":"crossref","unstructured":"Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro Oncol. 02 01 2017;19(2):162-174. doi:10.1093\/neuonc\/now241.","DOI":"10.1093\/neuonc\/now241"},{"issue":"20","key":"10.1016\/j.jocn.2026.112185_b0150","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1002\/cam4.3402","article-title":"Surgical resection of symptomatic brain metastases improves the clinical status and facilitates further treatment","volume":"9","author":"Sch\u00f6del","year":"2020","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.jocn.2026.112185_b0155","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jocn.2026.112185_b0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/CMR.0000000000000654","article-title":"Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib named Patient Program (DESCRIBE II)","volume":"30","author":"Atkinson","year":"2020","journal-title":"Melanoma Res"},{"issue":"10","key":"10.1016\/j.jocn.2026.112185_b0165","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3390\/cancers13102466","article-title":"A Retrospective Analysis of Dabrafenib and\/or Dabrafenib Plus Trametinib Combination in patients with Metastatic Melanoma to Characterize patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)","volume":"13","author":"Atkinson","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jocn.2026.112185_b0170","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11060-018-2795-7","article-title":"The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity","volume":"138","author":"Rahman","year":"2018","journal-title":"J Neurooncol"},{"issue":"10","key":"10.1016\/j.jocn.2026.112185_b0175","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3390\/cancers15102718","article-title":"Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment","volume":"15","author":"Ziogas","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.jocn.2026.112185_b0180","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1215\/15228517-2007-058","article-title":"Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features","volume":"10","author":"Raizer","year":"2008","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.jocn.2026.112185_b0185","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jocn.2026.112185_b0190","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2018-0306","article-title":"Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control","volume":"24","author":"Alvarez-Breckenridge","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jocn.2026.112185_b0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.wneu.2019.10.101","article-title":"Purely Meningeal Intracranial Relapse of Melanoma Brain Metastases after Surgical Resection and Immunotherapy as a Unique Disease Progression Pattern: our Experience and Review of the Literature","volume":"134","author":"Armocida","year":"2020","journal-title":"World Neurosurg"},{"issue":"7","key":"10.1016\/j.jocn.2026.112185_b0200","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jocn.2026.112185_b0205","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.29186","article-title":"Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and responses to Immunotherapy","volume":"6","author":"Vasudevan","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jocn.2026.112185_b0210","doi-asserted-by":"crossref","unstructured":"Mathieu D, Kondziolka D, Cooper PB, Flickinger JC, Niranjan A, Agarwala S, Kirkwood J, Lunsford LD. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007 Mar;60(3):471-81; discussion 481-2. doi: 10.1227\/01.NEU.0000255342.10780.52.","DOI":"10.1227\/01.NEU.0000255342.10780.52"},{"issue":"Suppl. S16","key":"10.1016\/j.jocn.2026.112185_b0215","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.1200\/JCO.2024.42.16_suppl.9505","article-title":"Efficacy and safety of Lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-na\u00efve unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A","volume":"42","author":"Thomas","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jocn.2026.112185_b0220","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.3390\/ijms26115018","article-title":"Tumor Microenvironment in Melanoma Brain Metastasis: a New potential Target?","volume":"26","author":"Caruso","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jocn.2026.112185_b0225","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/B978-0-12-397927-8.00011-7","article-title":"Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations","volume":"65","author":"Somasundaram","year":"2012","journal-title":"Adv Pharmacol"},{"issue":"4","key":"10.1016\/j.jocn.2026.112185_b0230","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0360-3016(00)00547-2","article-title":"Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases","volume":"47","author":"Gaspar","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.jocn.2026.112185_b0235","article-title":"Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases","volume":"8","author":"Tan","year":"2022","journal-title":"Front Oncol"},{"issue":"15","key":"10.1016\/j.jocn.2026.112185_b0240","first-page":"15976","article-title":"Prognostic factors for overall survival in melanoma patients with brain metastases treated with radiosurgery: a national cohort analysis","volume":"12","author":"Gorovets","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jocn.2026.112185_b0245","first-page":"85","article-title":"Descriptive statistical analysis of prognostic markers in melanoma brain metastases: LDH, extracranial disease, and KPS","volume":"164","author":"Berghoff","year":"2023","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2026.112185_b0250","doi-asserted-by":"crossref","unstructured":"Lehrer EJ, McGee HM, Peterson JL, et al. Stereotactic radiosurgery and immune checkpoint inhibitors in the management of brain metastases: a systematic review and meta-analysis. Radiother Oncol. 2020;145:13-20. PMID: 32446319. doi: 10.1016\/j.radonc.2020.05.001.","DOI":"10.1016\/j.radonc.2020.05.001"},{"issue":"3","key":"10.1016\/j.jocn.2026.112185_b0255","first-page":"553","article-title":"Patterns of failure and outcomes for the combination of SRS and BRAF\/MEK inhibitors in melanoma brain metastases","volume":"153","author":"Rauschenberg","year":"2021","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.jocn.2026.112185_b0260","first-page":"45","article-title":"Stereotactic radiosurgery for brain metastases in patients receiving targeted therapies: a national patterns-of-care analysis","volume":"4","author":"Kotecha","year":"2023","journal-title":"Neurosurg Pract"},{"issue":"8","key":"10.1016\/j.jocn.2026.112185_b0265","first-page":"491","article-title":"The abscopal effect: Mechanistic insights and therapeutic perspectives in radiation-immunotherapy combinations","volume":"20","author":"Parikh","year":"2023","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758682600336X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758682600336X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:27:07Z","timestamp":1793802427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096758682600336X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"alternative-id":["S096758682600336X"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112185","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of BRAF inhibitors on surgical outcomes in melanoma brain metastases: Evidence from a multicenter observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112185"}}